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Abstract
Several promising, oral disease-modifying therapies for multiple sclerosis are currently being
evaluated in clinical trials. The arrival of effective oral agents for multiple sclerosis will be a major
advance in the global effort to alter the natural history of this chronic disease.
Introduction and context
In the past 15 years, six new drugs have been approved
by the US Food and Drug Administration (FDA) as
disease-modifying therapies (DMTs) for multiple sclero-
sis (MS). All of these agents are either infusions or self-
administered injections, and many patients report
symptoms of pain, anxiety or injection-site reactions
associated with these treatments. Such side effects
negatively impact some MS patients’ satisfaction and
compliance with available DMTs, and there are even MS
patients who forgo DMTs altogether because of difficul-
ties associated with injections. Currently, there are
several promising oral DMTs for MS in phase II and III
clinical trials (Table 1). The arrival of oral DMTs for MS
will represent a major advance in MS therapeutics.
Recent advances
Cladribine is a purine nucleoside analogue that prefer-
entially depletes lymphocytes [1]. It is currently FDA-
approved in its injectible form for the treatment of hairy
cell leukemia. Cladribine has shown promise as a DMT
for MS in its injectible form in several clinical trials,
especially with regard to suppression of gadolinium-
enhancing lesions [2–4]. In an 18-month trial of
injectible cladribine in relapsing-remitting MS patients,
treated patients had significant reductions in relapse rate
and gadolinium-enhancing lesions on magnetic reso-
nance imaging (MRI) compared to placebo [4]. An oral
formulation of cladribine for MS is currently in phase II
and phase III clinical trials, both as monotherapy and in
combination with interferon beta-1a (INF beta-1a), and
has been designated by the FDA as a fast-track product
for expedited review. Cladribine has shown to be
generally well-tolerated in previous trials, but the risk
of infection and bone marrow suppression associated
with its long-term use is yet to be determined [5].
Laquinimod, a derivative of linomide, is thought to limit
the infiltration of leukocytes into the central nervous
system and to shift the lymphocyte populations towards
Th2/Th3 cytokine expression [6]. A phase II trial of oral
laquinimod showed that the drug was well-tolerated by
MS patients, and that it significantly reduced gadoli-
nium-enhancing lesions compared to placebo after 24
weeks [7]. Unlike linomide, which ultimately failed in
clinical trials as an MS drug because of serious adverse
cardiovascular events, laquinimod has not been asso-
ciated with any such side effects [7,8]. Oral laquinimod is
currently being evaluated in a series of phase III clinical
trials.
Fingolimod (FTY-720) is a sphingosine-1-phosphate
receptor modulator that prevents egress of lymphocytes
outside of lymph nodes, the effect of which significantly
reduces the number of circulating lymphocytes [9,10].
Specifically, it reduces the number of naïve and memory
T cells but not effector T cells, and it does not affect T-cell
function [9]. In a phase II trial of 255 MS patients, oral
fingolimod significantly reduced the number of gadoli-
nium-enhancing lesions and the annualized relapse rate
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being evaluated in phase III trials. The safety and
tolerability of fingolimod remains questionable, as two
serious adverse infections were reported in the extension
phase of the phase II study [10].
Teriflunomide is a metabolite of leflunomide, an FDA-
approved treatment for rheumatoid arthritis [11]. A
chemotherapeutic agent, oral teriflunomide blocks
pyramidine synthesis by inhibition of dihydro-orotate
dehydrogenase, and ultimately interferes with the inter-
action of T cells with antigen-presenting cells, thereby
inhibiting T-cell activation [6,12–14]. Teriflunomide has
also been shown to suppress experimental allergic
encephalomyelitis (EAE), a murine model of MS [14].
In a 36-week, phase II trial, oral teriflunomide signifi-
cantly reduced the number of combined unique active
lesions on MRI in MS patients compared to placebo and
was well-tolerated by patients [15]. It is currently
undergoing phase III trials as monotherapy, and in
combination therapy with both IFN beta-1a and
glatiramer acetate.
BG00012 (fumarate) is an immunomodulatory agent
that is used to treat psoriasis. Oral BG00012 has been
shown to suppress the number of CD4
+ and CD8
+
lymphocytes in peripheral blood, and to cause a shift in
T-cell cytokine production away from a Th1 profile and
towards a Th2 profile [16,17]. A phase II, 24-week
clinical trial of BG00012 showed a significant decrease in
gadolinium-enhancing lesions, new T2 lesions, and
hypointense T1 lesions on MRI in MS patients compared
to placebo, and was found to be generally well-tolerated
[18]. A phase III trial of oral BG00012 in MS is currently
underway.
Minocycline is an FDA-approved oral antibiotic that is
recognized to have both anti-inflammatory and neuro-
protective properties, and is safe and well-tolerated.
Minocycline has been shown to inhibit matrix
metalloproteinase-9 activity, which is important to
lymphocyte migration into the central nervous system,
and inhibits microglial activity and apoptosis in vitro
[19]. Minocycline has also been shown to inhibit EAE
[20]. In a small, open-label trial of minocycline in MS,
the proportion of active MRI scans during the treatment
was significantly lower than in the run-in phase [21].
Minocycline is currently in a phase III trial as mono-
therapy for MS, and in phase II trials as adjunctive
therapy with glatiramer acetate and INF beta-1a.
Mycophenylate mofetil is an oral immunosuppressive
agent that is FDA-approved to prevent organ transplant
rejection. It inhibits the synthesis of purines used in the
proliferation of T and B lymphocytes [22]. A phase II trial
in MS of mycophenylate mofetil as adjunctive therapy to
INF beta-1a showed a significant reduction in relapse
rate after 6 months on combination therapy compared to
INF beta-1a monotherapy [23]. Oral mycophenylate
mofetil is currently in phase III trials as an adjunctive
DMT with INF beta-1a.
HMG-CoA (3-hydroxy-3-methyl-glutaryl coenzyme A)
reductase inhibitors, the so-called ‘statins’, represent a
group of oral medications that are approved to treat
hyperlipidemia and that are generally well-tolerated.
Statins are also recognized to have immunoregulatory
activity. Specifically, statins have been shown to suppress
EAE through a shift from Th1 to Th2 cytokine production
and inhibition of lymphocyte migration across the blood
brain barrier [24]. A phase II, open-label clinical trial of
high-dose atorvastatin in MS showed a significant
reduction in the number and volume of gadolinium-
enhancing lesions after 9 months [25]. However, one
small study of high dose atorvastain versus placebo as
adjunctive therapy with INF beta-1a showed that MS
subjects in the atorvastatin group were significantly more
likely to have clinical or MRI disease activity after 6
months compared to those on placebo [26]. Pravastatin
is currently in a phase III trial as monotherapy for MS,
Table 1. New oral disease modifying therapies for multiple sclerosis
Oral DMTs Mechanism of action Clinical trial status
Cladribine Purine analog that depletes lymphocytes Phase III
Laquinimod Shifts lymphocytes to Th2/Th3 cytokine profile Phase III
Fingolimod Sphingosine-1 phosphate receptor modulator that inhibits egress of lymphocytes from lymph nodes Phase III
BG00012 Shifts lymphoctyes to Th2 cytokine profile Phase III
Mycophenolate
mofetil
Inhibits purine synthesis in the production of T and B lymphocytes Phase III as adjunctive
therapy
HMG-coA reductase
inhibitors
Inhibits lymphocyte migration across blood brain barrier, and shifts to Th1 cytokine profile Phase III
Vitamin D3 T-cell regulation Phase II
DMT, disease modifying therapy; MMP-9, matrix metallopeptidase 9.
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Teriflunomide Inhibits ]T-cell activation Phase III
Minocyline Decreases lymphocyte migration into the central nervous system by inhibition of MMP-9 Phase IIIand simvastatin is in a phase III trial as adjunctive
therapy with INF beta-1a.
Vitamin D deficiency has recently been associated with a
higher risk of developing MS in a sero-epidemiological
study, and vitamin D intake appears to be associated
with a decreased risk of developing MS [27,28]. Vitamin
D3 production is stimulated by sunlight exposure, and
the recent vitamin D observations in MS may explain the
long-observed phenomenon of higher MS prevalence in
geographic areas where sunlight exposure is relatively
low. Vitamin D is also known to have immunomodu-
latory properties, especially with regard to T-cell regula-
tion [29]. A phase II trial of high-dose, oral vitamin D3
therapy in MS as a DMT is currently ongoing.
Implications for clinical practice
Several promising oral agents are currently being
evaluated in clinical trials as DMTs for MS, and the
likelihood is that at least some of them will gain FDA
approval. The arrival of these oral agents will give MS
patients and MS physicians more therapeutic options,
which will be especially beneficial for those MS patients
who have difficulty with injections or who have
experienced intolerable side effects from the currently
available DMTs. Another important benefit of the
emergence of oral DMTs is that there is likely to be a
reduction in the overall expense of MS therapeutic care.
While some of these therapies are currently approved for
other indications, we do not recommend off-label use of
these oral drugs until results from phase III trials are
available. These agents may prove to be ineffective or
even harmful and may encourage patients to avoid FDA-
approved therapies. The availability of oral DMTs with
proven efficacy will represent a significant advance in the
MS physician’s ability to treat all MS patients. The advent
of oral DMTs will herald a new era of increased
adherence to, and satisfaction with, therapy for MS
patients.
Abbreviations
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